How we Prioritize our Support AstraZeneca recognizes the importance of cultivating partnerships with organizations dedicated to furthering the common good and to improving health and heath care for us all. To ensure that those efforts are effective and continuing, each year AstraZeneca provides charitable contributions to hundreds of non-profit groups for these purposes. Because the total amount of support sought far exceeds what is available, AstraZeneca has developed the following general guidelines to use in evaluating the proposals that we receive. Definitions Charitable Contributions are defined as funds given to enhance the common good, with no commercial gain on the part of AstraZeneca. Charitable contributions are not used to fund independent medical education grants. Such grant requests should be submitted to AstraZeneca through the Medical Education Grants Office (MEGO) online at astrazenecagrants.com. Criteria
Funding Priorities Our funding priority is programs which improve health, and particularly patient health, such as programs focused directly on patients or their caregivers (e.g., patient education materials, disease-awareness campaigns or temporary living quarters for patients and their families); or efforts intended to improve the provision of health care (e.g., increased access for underserved or disadvantaged populations). In keeping with our corporate mission to improve patient health in the therapeutic areas of our business, priority will be given to requests that focus on diseases or conditions in our medical areas of research, which are cardiovascular, oncology, gastrointestinal, central nervous system and respiratory disease. In addition, we will also consider programs that work to ameliorate important societal problems and/or improve quality of life (e.g., programs enhancing education, or the lives of seniors, minorities or the aging), and activities that enhance the public good in general, such as support for the arts and culture.
Find out how to request a charitable contribution from AstraZeneca. |

